Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Cytoplasm |
Domain |
PF16207 RAWUL domain RING finger- and WD40-associated ubiquitin-like |
Function |
Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:15386022, PubMed:16359901, PubMed:26151332, PubMed:16714294, PubMed:21772249, PubMed:25355358, PubMed:27827373). The complex composed of RNF2, UB2D3 and BMI1 binds nucleosomes, and has activity only with nucleosomal histone H2A (PubMed:21772249, PubMed:25355358). In the PRC1-like complex, regulates the E3 ubiquitin-protein ligase activity of RNF2/RING2 (PubMed:15386022, PubMed:26151332, PubMed:21772249). |
Biological Process |
GO:0003002 regionalization GO:0007379 segment specification GO:0007389 pattern specification process GO:0016925 protein sumoylation GO:0018205 peptidyl-lysine modification GO:0031396 regulation of protein ubiquitination GO:0031398 positive regulation of protein ubiquitination GO:0035282 segmentation GO:0040029 regulation of gene expression, epigenetic GO:0045814 negative regulation of gene expression, epigenetic GO:0048144 fibroblast proliferation GO:0048145 regulation of fibroblast proliferation GO:0048146 positive regulation of fibroblast proliferation GO:0051438 regulation of ubiquitin-protein transferase activity GO:0051443 positive regulation of ubiquitin-protein transferase activity GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal |
Molecular Function |
GO:0003682 chromatin binding GO:0071535 RING-like zinc finger domain binding GO:1990841 promoter-specific chromatin binding |
Cellular Component |
GO:0000151 ubiquitin ligase complex GO:0000152 nuclear ubiquitin ligase complex GO:0031519 PcG protein complex GO:0035102 PRC1 complex |
KEGG |
hsa04550 Signaling pathways regulating pluripotency of stem cells |
Reactome |
R-HSA-2559583: Cellular Senescence R-HSA-2262752: Cellular responses to stress R-HSA-392499: Metabolism of proteins R-HSA-2559580: Oxidative Stress Induced Senescence R-HSA-597592: Post-translational protein modification R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins R-HSA-2990846: SUMOylation R-HSA-3108214: SUMOylation of DNA damage response and repair proteins R-HSA-4570464: SUMOylation of RNA binding proteins |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between BMI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between BMI1 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of BMI1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of BMI1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of BMI1 in various data sets.
|
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BMI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BMI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BMI1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BMI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of BMI1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between BMI1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | BMI1 |
Name | BMI1 proto-oncogene, polycomb ring finger |
Aliases | RNF51; PCGF4; polycomb group ring finger 4; B lymphoma Mo-MLV insertion region 1 homolog (mouse); FLVI2/BMI1 ...... |
Chromosomal Location | 10p13 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting BMI1 collected from DrugBank database. |
There is no record. |